Peptides immunoreactive with autoantibodies from patients suffering from rheumatoid arthritis
AssigneeStichting voor de Technische Wetenschappen
InventorsWaltherus Jacobus Wilhelmus Van Venrooij, Gerardus Antonius Schellekens, Jozef Maria Hendrik Raats, Rene Michael Antonius Hoet
Life of this patent
Estimating the term…
Abstract
The invention relates to a peptide derived from an antigen recognized by autoantibodies, which peptide is reactive with autoimmune antibodies from a patient suffering from rheumatoid arthritis. The peptide according to the invention possesses a modified arginine residue. The invention also relates to antibodies against the peptide and a method of detecting autoimmune antibodies.
Claims13
A synthetic peptide which comprises an amino acid sequence that is the same as that of a fragment having no more than 19 amino acids of the amino acid sequence of SEQ ID NO:17 and having sufficient length to act as an epitope for antibody binding, except that said peptide has at least one arginine residue of SEQ ID NO:17 replaced by a citrulline residue,
- which peptide is specifically immunoreactive with anti-filaggrin antibodies present in the serum of subjects suffering from rheumatoid arthritis.
A synthetic peptide that consists of an amino acid sequence that is the same as that of a fragment of the amino acid sequence SEQ ID NO:17 having sufficient length to act as an epitope for antibody binding, except that said peptide has at least one arginine residue of SEQ ID NO:17 replaced by a citrulline residue,
- which peptide is specifically immunoreactive with anti-filaggrin antibodies present in the serum of subjects suffering from rheumatoid arthritis.
A method to prepare a synthetic peptide which comprises an amino acid sequence that is the same as that of a fragment of the amino acid sequence SEQ ID NO:17 having sufficient length to act as an epitope for antibody binding, except that said peptide has at least one arginine residue of SEQ ID NO:17 replaced by a citrulline residue,
- which peptide is specifically immunoreactive with anti-filaggrin antibodies present in the serum of subjects suffering from rheumatoid arthritis,
- which method comprises sequential peptide synthesis coupled to solid support wherein in said sequential synthesis, a citrulline is introduced in lieu of said at least one arginine.
Dependencies are inferred from the claim text.